Updating the database of the Illinois Compiled Statutes (ILCS) is an ongoing process.
Recent laws may not yet be included in the ILCS database, but they are found on this site as Public
soon after they become law. For information concerning the relationship between statutes and Public Acts, refer to the
Because the statute database is maintained primarily for legislative drafting purposes,
statutory changes are sometimes included in the statute database before they take effect.
If the source note at the end of a Section of the statutes includes a Public Act that has
not yet taken effect, the version of the law that is currently in effect may have already
been removed from the database and you should refer to that Public Act to see the changes
made to the current law.
(225 ILCS 85/19.1)
(Section scheduled to be repealed on January 1, 2020)
Dispensing opioid antagonists.
(a) Due to the recent rise in opioid-related deaths in
Illinois and the existence of an opioid antagonist that can
reverse the deadly effects of overdose, the General Assembly
finds that in order to avoid further loss where possible, it is
responsible to allow greater access of such an antagonist to
those populations at risk of overdose.
(b) Notwithstanding any general or special law to the
contrary, a licensed pharmacist may dispense an opioid antagonist
in accordance with written, standardized procedures or
protocols developed by the Department with the Department of
Public Health and the Department of Human Services if the
procedures or protocols are filed at the pharmacy before
implementation and are available to the Department upon
(c) Before dispensing an opioid antagonist pursuant to this
Section, a pharmacist shall complete a training program
approved by the Department of Human Services pursuant to
Section 5-23 of the Substance Use Disorder Act. The training program shall include, but not be
limited to, proper documentation and quality assurance.
(d) For the purpose of this Section, "opioid antagonist" means a drug that binds to opioid receptors and blocks or inhibits the effect of opioids acting on those receptors, including, but not limited to, naloxone hydrochloride or any other similarly acting and equally safe drug approved by the U.S. Food and Drug Administration for the treatment of drug overdose.
(Source: P.A. 99-480, eff. 9-9-15; 99-642, eff. 7-28-16; 100-759, eff. 1-1-19